Our company has a proprietary and complete S2 recombinant protein technology base – ExpreS2, which was developed over ten years at Pharmexa A/S. We have in-depth practical experience with the non-viral Drosophila S2 expression technology for the production of recombinant proteins for preclinical development and for use in clinical trials.
ExpreS2ion Biotechnologies specializes in establishment of high-producing cell lines together with upstream process development and working with customers to solve technical problems in molecular biology, protein expression or other issues relating to S2 cells. S2 related reagents are also available.
NEWS / EVENTS
May 2013 : ExpreS2ion Biotechnologieswelcomes Max Søgaard PhD, who will develop downstream processing capabilities.Continue reading
30 April 2013 : ExpreS2ion Biotechnologies is presenting at PEGS 2013. “Development of a Drosophila S2 Insect Cell-Based Malaria Vaccine Production Process”Continue reading
April 2013 : ExpreS2ion Biotechnologies is sponsoring the World Vaccine Congress 16-18 April 2013, Washington DC, USA...Continue reading
EU funding for clinical trials of a placental malaria vaccine
Licensing agreement between ExpreS2ion Biotechnologies and the Jenner Institute, University of Oxford Continue reading
Malaria Eurostars PR Pdf version article